Cookies are essential for the operation of our website. By using our website, you agree to the use of cookies.
This website uses cookies to improve and personalize content, and for tracking and analytics. By clicking "Accept All Cookies", you are providing consent for Exelixis to collect and retain personal data for Exelixis to optimize the use of this website. You can learn more about Exelixis' use of cookies by reviewing Exelixis' Privacy Statement.
Reject Nonessential Cookies Accept All Cookies
Skip to main content
Click to go back to the Pipeline page Back To Explore Our Pipeline

Disable motion

XL309: USP1 Inhibitor

XL309 is a selective, orally bioavailable small molecule USP1 inhibitor, in-licensed under an exclusive global license agreement to supplement our drug discovery efforts.
Molecular structure shown is an artistic rendering.
XL309 was shown in mouse xenograft models to inhibit the activity of ubiquitin-specific peptidase 1 (USP1), a deubiquitinase that facilitates DNA damage repair and has emerged as a synthetic lethal target in the context of BRCA-mutated tumors.
Phase 1 dose-escalation and expansion study of XL309 as a single agent and combination therapy in select advanced solid tumors.
Cohort Expansions
For more information, visit
This website includes information on investigational uses of compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Safety and efficacy of investigational compounds and/or investigational uses of approved products have not been established. The information presented should not be construed as a recommendation for use.
Explore All
Pipeline Clinical Trials
Click to go to Resource